Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .One of the biggest stories so far in December is Sam Altman, the CEO of OpenAI, just declaring a 'code red,' which has gotten outsized coverage in the financial press. It was his callBret Jensen has over 13 years as a market analyst, he ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .It has been another good year for investors as we head into the final month of 2025. The Dow and S&P 500 open December on seven-month winning streaks, thanks to a big surge during the holiday shortenedBret Jensen has over 13 years as a ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Markets had a big rebound during the holiday shortened week after the prior week's big sell-off. It was the best Thanksgiving week of trading for equities in more than a decade. The Dow was up three percent; theBret Jensen has over 13 y ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Equities have staged their best rally into the Thanksgiving holiday since 2012, and the major indexes had their best week since late June. Of course, this follows last week's selloff in the market that brought the NASDAQ (Bret Jensen ha ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .It is difficult to believe we are already at Thanksgiving Day in 2025. Where does the time go? The markets have continued to rally as they have since late 2022, with the debut of ChatGPT. The market had oneBret Jensen has over 13 years ...

Core Insights - Rigel Pharmaceuticals, Inc. (RIGL) has experienced a significant increase in share price over the past month, driven by better-than-expected Q3 results [1]. Company Performance - The Q3 results for Rigel Pharmaceuticals exceeded market expectations, contributing to the recent rally in its stock price [1]. Market Commentary - The Biotech Forum, led by an experienced market analyst, provides insights into high beta sectors and offers a model portfolio of 12-20 biotech stocks with high upside potential [1].

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, ...

Group 1 - NVIDIA Corporation reported strong third quarter results, which have temporarily halted the market's deterioration in November [2] - The performance of NVIDIA is seen as a significant factor in the overall market sentiment, especially during the traditional 'Santa Claus rally' period [2] - The company is recognized as a leader in the AI sector, contributing to its robust financial performance [2] Group 2 - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [2] - The forum is led by an experienced market analyst with over 13 years in the biotech sector, focusing on high beta sectors with potential for large investor returns [2]

Group 1 - The article discusses the frequent discussions of specific covered call trades within The Biotech Forum, highlighting the potential for attractive biotech stock investments [1] - Zymeworks Inc. (ZYME) is mentioned as a small-cap biotech company that was previously analyzed, with expectations for multiple upcoming FDA events [1] - The Biotech Forum, led by an experienced market analyst, offers a model portfolio of 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [1] Group 2 - The analyst has disclosed a beneficial long position in the shares of BMY and JAZZ, indicating a vested interest in these stocks [2] - The article emphasizes that past performance does not guarantee future results, and no specific investment recommendations are provided [3]

Group 1 - The article discusses the frequent discussions of specific covered call trades within The Biotech Forum, highlighting the potential for attractive investment opportunities in biotech stocks [1] - Zymeworks Inc. (ZYME) is mentioned as a small-cap biotech company that was analyzed earlier in the year, indicating ongoing interest in its performance and potential upcoming developments [1] - The Biotech Forum, led by an experienced market analyst, offers a model portfolio of 12-20 high upside biotech stocks, along with live chat discussions and weekly research updates [1] Group 2 - The analyst has disclosed a beneficial long position in the shares of BMY and JAZZ, indicating a personal investment interest in these companies [2] - The article emphasizes that past performance is not indicative of future results, which is a common disclaimer in investment discussions [3] - Seeking Alpha, the platform hosting the article, clarifies that its analysts may not be licensed or certified, suggesting a need for investors to conduct their own due diligence [3]